Immuo-thermal ablations – boosting the anticancer immune response

Ryan Slovak1,2, Johannes M. Ludwig1,3, Scott N. Gettinger4,5, Roy S. Herbst4,5 and Hyun S. Kim1,4,5,6*

Abstract
The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particular, immune modulating drugs have the potential to enhance the systemic anticancer immune effects induced by locoregional thermal ablation. The immune responses induced by ablation monotherapy are well documented, but independently they tend to be incapable of evoking a robust antitumor response. By adding immunomodulators to traditional ablative techniques, several researchers have sought to amplify the induced immune response and trigger systemic antitumor activity. This paper summarizes the work done in animal models to investigate the immune effects induced by the combination of ablative therapy and immunomodulation. Combination therapy with radiofrequency ablation, cryoablation, and microwave ablation are all reviewed, and special attention has been paid to the addition of checkpoint blockades.

Keywords: Combination Therapy, Cryoablation, Radiofrequency ablation, Microwave ablation, Checkpoint inhibition

Background
In clinical routine, therapeutic techniques such as thermal ablation and surgical resection are used to target local malignancies for destruction. Due to the locoregional nature of these very precise interventions, small, distal metastases often escape destruction. Unsurprisingly these micrometastases can be responsible for tumor recurrence after treatment [1].

One potential way to overcome the challenge of micrometastases is to induce systemic antitumor immunity by activating the immune system. Thermal ablative techniques such as cryoablation, radiofrequency ablation (RFA), microwave ablation (MWA), and focused ultrasound (FUS) have all been shown to trigger an immune response [2–5]. By destroying readily accessible tumors, ablative therapies make tumor antigens available as an in-situ cancer vaccine which can lead to the initiation of a systemic antitumor immune response that can affect and potentially eliminate occult, metastatic tumors [3, 4]. The phenomenon whereby a locally applied therapy triggers a distal antitumor response is termed the abscopal effect [6].

The magnitude of the abscopal effect induced by ablative therapy alone has proven to be either weak and insufficient or counterproductive [2, 7]. Recently, interest has shifted towards exploring the potential synergy between ablative techniques and immunotherapies. By combining these two forms of oncologic treatment, investigators aim to overcome immune regulation and enhance long-term, systemic antitumor immunity [2, 4]. Research into these combination therapies is just beginning and while some success has been seen in clinical trials, many studies continue to be conducted in animal models [8–10]. With this review, we will summarize the data gathered from the study of combination ablation immunotherapy in animal models (Table 1).

Immunostimulatory effects induced by ablation
There are a wide variety of ablation techniques designed to destroy solid organ tumors. Many of these methods have been in use for decades, but their ability to trigger systemic immune responses is just beginning to be fully appreciated. Though the goals of ablation are similar to those of surgical resection, ablation differs in that the tumor material is left in situ. Even with the bulk of the tumor destroyed, antigenic remnants persist. This aspect...
of ablation is responsible for its ability to trigger a systemic antitumor immune response where surgical resection would not [2, 11].

Cryoablation utilizes expanding argon gas to induce a freeze-thaw cycle in targeted lesions that results in necrotic cell death in a small radius around the probe. The cells that die via necrosis release preserved intracellular organelles, antigens, and damage associated molecular patterns (DAMPs) such as DNA and heat shock proteins (HSPs) [7]. Dendritic cells (DCs) that phagocytize these DAMPs activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κβ) pathway, which then promotes the expression of co-stimulatory CD80/CD86 molecules [12, 13]. Dendritic cells that present antigens on major histocompatibility complex (MHC) molecules and show co-stimulators stimulate T-cells and promote a systemic immune response [2, 14, 15]. Some authors have referred to this ability of cryotherapy to load dendritic cells as producing an “in-vivo dendritic cell vaccine” [16]. The immunostimulatory response induced by cryoablation alone has been noted as the most potent among ablative therapies, as evidenced by significantly higher post-ablative levels of serum interleukin-1 (IL-1), IL-6, NF-κβ, and tumor necrosis factor-α (TNF-α) [2]. Peripheral to the site of cryoablation, sublethal temperatures induce apoptotic cell death [2, 7, 17].

Cells that die by apoptosis also release antigens that can be picked up by dendritic cells, but they do not typically release DAMPs. Without phagocytizing DAMPS, the NF-κβ pathway is not activated and expression of CD80 and CD86 is not induced [12, 13]. Without these co-stimulators, T-cell anergy or even clonal deletion may occur, thereby suppressing the immune response (See Figs. 1 and 2) [3, 14]. The necrotic cell death therefore seems critical for inducing a systemic immune response with cryotherapy. Thus, cryoablation alone can induce both an immunostimulatory and an immunosuppressive effect. Whether stimulation or suppression prevails is dependent on whether there is more necrosis or apoptosis, and the proportion of these responses may vary over time [18]. By combining cryoablation with immunotherapy, many investigators have sought to enhance the dendritic cell loading or inhibit the regulatory response induced by the lack of co-stimulators, thereby improving immunostimulation and limiting immunosuppression.

Radiofrequency ablation induces cell death via direct hyperthermic injury and coagulative necrosis. Just as in cryotherapy, necrotic cell death caused by RFA releases intracellular antigens and DAMPs such as HSPs and high mobility group protein B1 (HMGB1) as well as RNA and DNA that can be picked up by dendritic cells and go on to stimulate a systemic immune response. Outside of the

---

Table 1: A concise summary of significant findings from preclinical studies combining immunotherapy with thermal ablation

| Radiofrequency Ablation | Survival | Rechallenge | Tumor Volume | Cytolytic Activity | CD4+ Tumor Infiltration | CD8+ Tumor Infiltration |
|-------------------------|---------|-------------|-------------|-------------------|------------------------|------------------------|
| +CpG B [31]             | ↑       | NS          | –           | ↑                 | –                      | –                      |
| +Ex Vivo Stimulated Dendritic Cells [38, 46] | ↑       | –           | ↓           | ↑                 | ↑                      | ↓                      |
| +Poxviral CEA/TRICOM Vaccine [40] | NS      | –           | –           | –                 | –                      | –                      |
| +CC Chemokine Ligand 3 [41] | –       | –           | ↓           | –                 | ↑                      | ↑                      |
| +Anti-CTLA-4 Antibodies [10] | –       | ↑           | –           | –                 | –                      | –                      |
| +Anti-CD25 Antibodies [10] | –       | ↑           | –           | –                 | –                      | –                      |
| +Anti-PD-1 Antibodies [16] | ↑       | –           | ↓           | –                 | –                      | –                      |

| Cryoablation            | Survival | Rechallenge | MHC I Presentation | MHC II Presentation | CD4+ Tumor Infiltration | CD8+ Tumor Infiltration |
|-------------------------|----------|-------------|--------------------|---------------------|------------------------|------------------------|
| +CpG ODN [12]           | ↑        | ↑           | ↑                  | ↑                   | –                      | –                      |
| +Ex Vivo Immature Dendritic Cells [37] | ↑        | ↑           | –                  | –                   | –                      | –                      |
| +TLR7 Agonist Imiquimod [11] | –       | ↑           | –                  | –                   | –                      | –                      |
| +CTLA-4 Antibodies [10, 15] | ↑         | ↑           | –                  | –                   | ↑                      | ↑                      |
| +Anti-CD25 Antibodies [10] | –         | ↑           | –                  | –                   | ↑                      | ↑                      |
| +Cyclophosphamide [44] | ↑         | ↑           | –                  | –                   | –                      | –                      |

| Microwave Ablation      | Survival | Rechallenge | Tumor Volume | Th1/Th2 Cytokine Ratio | CD4+ Tumor Infiltration | CD8+ Tumor Infiltration |
|-------------------------|----------|-------------|--------------|------------------------|------------------------|------------------------|
| +OK 432 [42]            | ↑        | ↑           | –            | ↑                     | ↑                      | ↑                      |
| +GM-CSF Microspheres [45] | ↑        | ↑           | –            | –                     | –                      | –                      |
| +GM-CSF Microspheres & Anti-CTLA-4 Antibodies [45] | ↑        | ↑           | ↓            | –                     | –                      | –                      |

† Significantly improved response (p < 0.05), ↓ significant decrease (p < 0.05), NS not significant
focal zone, diffusion of heat creates a transition zone where sublethal temperatures induce apoptotic cell death. Heat Shock Protein 70 is particularly elevated in this transitional zone, and it is believed that it plays a key role in mediating RFA’s immunostimulatory effect [3]. Hours to days after RFA, levels of IL-1β, IL-6, IL-8, and TNF-α have all been shown to be increased [2]. Radiofrequency ablation alone has also been shown to cause a persistent increase in tumor specific antibodies, CD4+ T cells, CD8+ T Cells and to decrease levels of CD25+ FoxP3+ regulatory T cells [19, 20]. In spite of these results, RF has also been proven to cause hypoxia driven metastatic tumor growth distal to the site of treatment [21, 22]. Researchers are beginning to investigate the ability of additive immunotherapies to enhance the immunostimulatory and diminish the oncogenic effects of RFA.

Microwave ablation utilizes an oscillating electromagnetic field to release kinetic energy as heat that damages nearby cells via direct hyperthermic injury. Compared to cryoablative and RFA, the immune response induced by MWA is relatively paltry. While IL-1, IL-6, and HSP 70 are all elevated following MWA, the magnitude of their induction is significantly less than what follows after cryoablative and RFA [23, 24]. Perhaps due to this comparatively poor immune induction, MWA in combination with immunotherapy has not been studied as extensively as the other ablative methods.

Focused ultrasound (FUS) is an additional image-guided ablative technique that is available in a range of input energies. High-intensity focal ultrasound (HIFU) is similar to the other hyperthermic modalities in that it generates

---

**Fig. 1 a** Indirect ablative damage triggers apoptotic cell death and does not induce co-stimulator expression on DCs. In contrast, direct ablative damage releases DAMPs that activate the NF-κB pathway and induce co-stimulator expression in DCs, thereby promoting the activation and proliferation of T cells [2, 3, 7, 12, 13]. **b** Legend for Figs. 1 and 2.
cell death at a focal point via coagulative necrosis and apoptotic death in a transitional zone [3, 4, 25]. Cells destroyed by HIFU release intratumoral antigens including several HSPs and damage associated molecular patterns (DAMPs) that can go on to stimulate innate and adaptive immune responses [4, 25]. Following HIFU, augmented levels of IL-2, IFN-γ, and TNF-α and decreased levels of IL-4, IL-5, and IL-10 have been observed. Additionally, the immunosuppressive factors VEGF, TGF-β1 and TGF-β2 were all shown to be decreased after HIFU [4, 25]. However, just like microwave ablation, the immune response induced by HIFU has been shown to be...
minimal in comparison to cryoablation and RFA [2]. Some have hypothesized that the reason for this restricted response is that the coagulative necrosis generated by HIFU destroys much the structure and vascularity of tumors, thus limiting the ability of immune cells to reach and interact with the tumor [5]. With this in mind, low energy focused ultrasound (LOFU) was designed to deliver a limited amount of energy that would be immunogenic while also being incapable of inducing coagulative necrosis. LOFU has been shown to reduce the expression of T cell anergy inducing genes, thereby discouraging tumor induced immune tolerance. Additionally, following treatment with LOFU, calreticulin was seen to be redistributed in B16 cells and the expression of HSP70, MHC II, and B7 were all shown to be increased, indicating treatment induced changes in the levels of stress proteins and dendritic maturation states [5]. Unfortunately, very little work has been done to study the benefits of combining immunotherapy with either HIFU or LOFU in animal models.

Yet another form of thermal ablation available to treat malignant tumors is photothermal ablation. This relatively new technique involves selective deposition of nanoparticles which can then be targeted with lasers to trigger hyperthermia in a specific lesion. Some success has already been seen when utilizing this technique in combination therapies, including one instance where photothermal ablation was performed in conjunction with multiple immunotherapies [30–32]; however, due to the broad differences that exist among the many variations of photothermal nanoparticles, we believe this topic deserves its own review.

### Immunotherapies

As a parallel to thermal ablation, many oncologists treat malignancies with immune modulating pharmaceuticals. As with ablation, the mechanisms of each immunotherapy varies greatly. However, these therapies can largely be divided into two categories; those that target the innate immune system, and those that target the adaptive. The innate immune system utilizes broad pattern recognition to respond rapidly, whereas adaptive responses are more specialized and can form the basis of long term immunologic memory [33]. While these two response types do differ greatly, they are both part of the larger immune response. Immunotherapies chiefly target either the innate or the adaptive immune responses, but methods that exploit the cross-talk between these two systems often exert the most robust effects.

Checkpoint inhibitors have seen a recent burst in clinical use as immunotherapies that target the adaptive immune response. There are several regulatory “checkpoints” that normally prevent the inappropriate activation of a cell-mediated immune response. By inhibiting these checkpoints, the immune system is freed to respond more robustly. Specifically, therapies exist that target and inhibit specific regulatory receptors. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) binds costimulatory B7 molecules (CD80/86) with a much higher affinity than CD28. When B7 binds CTLA-4 instead of CD28, it does not produce its usual stimulatory signal. Therefore, CTLA-4 functions to competitively inhibit T cell stimulation, and promote T cell anergy [34]. Ipilimumab and Tremelimumab are both examples of anti-CTLA-4 antibodies that have demonstrated success at overcoming this regulatory hurdle. Ipilimumab is currently approved to treat metastatic melanoma while Tremelimumab is currently undergoing additional research [14, 35]. Similarly, programmed death receptor 1 (PD-1) is another inhibitory receptor found on T cells. When PD-1 is activated by PD-L1, a ligand often found on tumor cells, it inhibits T cell function and triggers apoptosis [34]. Pembrolizumab, Nivolumab, Durvalumab, and Avelumab are all anti-PD-1 drugs that have shown promise. The PD-1 inhibitors are approved for the treatment of melanoma, renal cell carcinoma, bladder cancer, non-small cell lung cancer, Hodgkin's lymphoma, Merkel cell carcinoma and solid tumors. Both the CTLA-4 and PD-1 pathway have been implicated in the ability of tumors to evade the host immune system [34]. As such, both are prime targets for immunomodulation and for combining with ablation (Fig. 2). Another, somewhat more direct method for overcoming immune regulation is to directly target CD25+ FoxP3+ Regulatory T cells for depletion. Regulatory T cells are a subset function to suppress the immune system, and by administering anti-CD25 antibodies this inhibitory mechanism can be diminished [14, 36]. Varying extents of CD25+ Regulatory T cell depletion have
also been shown following administration of the aforementioned CTLA-4 inhibitors [37, 38]. It should be noted that any therapy which depletes regulatory T cells via CD25+ is likely to also deplete some active, effector T cells which may transiently express CD25 [39].

Dendritic cells have been a major topic of investigation as possible targets for immunotherapy in the innate immune system. Dendritic Cells are professional antigen presenting cells and first line defenders that are able to pick up, process and present tumor antigens. Once activated by an infection, dendritic cells increase their expression of co-stimulators and can then go on to activate a larger lymphocyte response [14]. As one example the topical Toll-like Receptor 7 (TLR7) agonist Imiquimod has also been used to stimulate immature dendritic cells into inducing surface co-stimulators such as CD-80 and CD-86. Dendritic cells activated by Imiquimod go on to trigger type-1 helper T cell immunity [15]. As another example of innate immunomodulation, synthetic, repetitive bacterial nucleotides called CpG-oligodeoxynucleotides (CpG ODN) have been made to resemble specific unmethylated CpG dinucleotides from bacterial DNA. The Toll-Like receptor 9 is specific to these “CpG motifs” and thus CpG ODN are TLR-9 agonists. Professional antigen presenting cells such as dendritic cells and B cells utilize these TLR-9 receptors to induce an innate immune response to bacterial DNA [40, 41]. When CpG activates dendritic cells via TLR-9, they secrete IFN-α that triggers migration and clumping of more dendritic cells [42]. CpG activated TLRs also stimulate B cells to increase expression of co-stimulators, resist programmed cell death, up-regulate the chemokine CCR7, and secrete Th-1 inducing mediators [41, 43]. Artificial CpG ODNs take advantage of this to stimulate an innate immune response. Critically, the route of administration of CpG B after local destructive therapy has been shown to affect its efficacy in mice. It has been shown that peritumoral administration confers increased rates of dendritic cell activation as well as an improved tumor specific CD8+ T cell response and protection against rechallenge as compared to both intravenous and distal cutaneous administration (p < 0.05) [44].

**Combination with innate immunotherapies**

The addition of CpG B to radiofrequency ablation in a VX-2 rabbit model of liver cancer significantly increased mean survival, cytolytic activity, and tumor-specific T cell activation compared to either therapy alone. Additionally, the combined therapy demonstrated increased protection against pulmonary metastases when subjected to a rechallenge of injected malignant cells. Animals treated with combination RFA/CpG survived longer on average than those treated with RFA or CpG alone. Additionally, significantly less animals in the combination therapy group showed residual malignant tissue after 120 days compared to both monotherapy groups (p < 0.05). Combination therapy also produced the largest number of activated tumor specific lymphocytes compared to RFA alone, CpG alone, and the untreated controls as measured by a stimulation index (SI) (p < 0.05). A luciferase assay quantified the cytolytic activity of the activated T cells by assessing the levels of adenylate cyclase released by isolated peripheral T cells with relative luminescence units (RLU). Again, combination therapy produced the best outcome, followed by RFA alone, and CpG alone. There was no lytic activity in the untreated animals [40].

The addition of CpG B to cryoablative therapy has also been studied. Using a B16OVA mouse model of melanoma, this combination was shown to enhance dendritic cell maturation and cross presentation leading to a so-called “in-vivo dendritic cell vaccine.” While CpG alone had no effect on the growth of primary tumors or rechallenge, combination therapy completely protected against rechallenge with B16OVA. Interestingly, combination therapy also partially protected against a rechallenge after 40 days with wild-type, poorly immunogenic B16F10 tumors. Compared to untreated controls and monotherapy, combination therapy significantly increased CD80 expression on dendritic cells as well as MHC I and II presentation but did not significantly affect dendritic cell loading as compared to RFA monotherapy (p < 0.05). The combination of CpG B and cryoablation in this model also induced regression of existing secondary tumors in 40% of treated mice and completely protected against the outgrowth of local recurrences within 15 days after treatment [16].

Imiquimod, a TLR7 agonist and dendritic cell stimulator has also been combined with cryotherapy in a B16OVA murine model of melanoma. The combined administration of topical Imiquimod with cryoaablative conferred significant protection against rechallenge. Combination therapy protected against rechallenge in 90% of the cases, compared to cryotherapy alone which only protected 30% of cases (p < 0.0001). The combination also increased T cell proliferation as well as IFN-γ production when compared to either therapy alone. IFN-γ was measured in-vitro after stimulation with OVA protein. Cryotherapy plus Imiquimod induced more than double the production of IFN-γ compared to cryoablation alone [15].

In addition to stimulating in-vivo dendritic cells, much research has been done to investigate the benefits of combining ablative therapy with an injection of ex-vivo dendritic cells directly into the tumor site. Ablative therapy in combination with an injection of either immature or stimulated dendritic cells has been studied. One study used a MB49 murine model of urothelial carcinoma to show that RFA and injection of immature ex vivo dendritic cells each independently result in enhanced antitumor T cell response and tumor regression, but that the combination of the two does not amplify
with RFA. The addition of HT-DC cells (HT-DC) to the administration of ex-vivo, unheated dendritic cells (p < 0.001). Another study compared the administration of ex-vivo immature dendritic cells and cryotherapy conferred significantly increased the number of CD8+ T Cells infiltrating untreated secondary tumors as compared to RFA alone or RFA with immature dendritic cells (p < 0.001). Additionally they showed that combination therapy significantly increased the number of CD8+ T Cells infiltrating untreated tumors compared to RFA alone or RFA with immature dendritic cells (p < 0.001) [47]. Another study compared the administration of ex-vivo immature dendritic cells and cryotherapy confered significantly prolonged survival following amputation of the foot bearing the primary tumor and after rechallenge (p = 0.005 and p = 0.029 respectively) [46].

Nakagawa et al. demonstrated that administration of dendritic cells stimulated by OK-432 (an antigen derived from the Su strain of group A Streptococcus pyogenes) after RFA conferred a significant decrease in mean tumor volume compared to RFA alone or RFA with administration of immature dendritic cells (p < 0.001). Additionally they showed that combination therapy significantly increased the number of CD8+ T Cells infiltrating untreated secondary tumors as compared to RFA alone or RFA with immature dendritic cells (p < 0.001) [47]. Radiofrequency ablation has also been combined with a poxviral vaccine expressing carcinoembryonic antigen (CEA) and a triad of costimulatory molecules (TRICOM). This combination was shown to induce regression of distal metastatic tumors when either therapy alone did not. Additionally, adding the vaccine to sequential RFA significantly reduced the combined volume of primary and distal tumors (p < 0.0054). Combination therapy also prolonged relapse-free survival as compared to RFA monotherapy. Combination therapy eliminated 100% of primary tumors, compared to 43% by RFA alone. The level of CEA specific CD4+ response was also highest in the combination group compared to either monotherapy (p < 0.0003). This combined therapy of CEA/TRICOM vaccine and RFA also greatly increased the transcription of two tumor-suppressor micro RNAs, miR-141 and miR-205, as compared to either therapy alone. The tumor suppressing micro RNA, miR-150 was increased by all three therapies, and miR-133b was decreased by the combined therapy [49].

Administration of an active variant of CC chemokine ligand 3, ECI301, after radiofrequency ablation significantly reduced volume of tumors and significantly increased CD4 + and CD8+ T cell infiltration in a murine model of hepatocellular carcinoma (p < 0.05 & p < 0.01). These effects were eliminated CCR1-deficient mice, but not in CCR5-deficient mice, indicating the effect is mediated by CCR1 [50].

Li, et al. used microwave ablation in combination with OK-432, a penicillin inactivated and lyophilized preparation of a low virulence strain of group A streptococcus pyogenes, as an immunostimulant to induce the innate immune system to produce inflammatory cytokines in a murine model of breast cancer. Compared to controls, combination therapy significantly prolonged survival after ablation and significantly decreased the volume of tumors arising in animals after rechallenge (p < 0.001 & p < 0.05). After the rechallenge, the majority of animals treated with combination therapy completely rejected secondary tumors, whereas none of the control mice did. Combination therapy also significantly increased the infiltration of CD8+ T cells into tumors compared to ablation monotherapy, but did not significantly increase the infiltration of CD4+ T cells. Combination therapy also significantly increased the percentage of splenic CD4+ and CD8+ T cells compared to monotherapy (p < 0.05 & p < 0.01). They also characterized the ratio of Th1 (IFN-γ) to Th2 (IL-4) cytokines produced by CD4+ T cells in the different treatment groups. Combination therapy had a higher percentage of IFN-γ producing cells compared to monotherapy and a lower percentage of IL-4 producing cells compared to controls (p = 0.004 & p = 0.05). Overall the ratio of Th1 to Th2 was significantly higher in compared to the controls with combination therapy, but not with ablation alone (p < 0.05). Specific Th1 cytokines IL-18, IL-2, and IL-12 were all shown to be significantly increased with combination therapy compared to ablation alone (p < 0.01, p < 0.05, and p < 0.01) [51].

Combination with adaptive immunotherapies
Several immunotherapies that target the adaptive system have also been investigated. Den Brok, et al. showed that inhibition of CTLA-4 with specific antibodies prior to either RFA or cryoaulation amplifies the response to treatment [14, 52]. The combination of either cryoablation or RFA with CTLA-4 inhibition in a B16OVA model of melanoma conferred a significant increase in survival after rechallenge as compared to untreated controls and combination with sham IgG antibodies (p < 0.05) [14]. The authors additionally demonstrated an increase in tumor specific T cells 10 days after both cryotherapy and RFA combination treatment by identifying OVA kb tetramer positive CD8b + T cells. Following both RFA/anti-CTLA-4 and Cryoablation/anti-CTLA-4 therapy the percentage of OVA+ CD8b + T cells also increased, whereas the percentage did not increase in controls. It is notable that the loading of tumor antigens
| Reference | Tumor Model                  | Immunotherapy               | Endpoints                                                                 | RFA Monotherapy                                                                 | Combination Therapy                                                                 |
|-----------|------------------------------|-----------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Behm, B., et al. [31] | VX2 Rabbit Liver Cancer    | CpG B                       | Mean Animal Survival After Inoculation                                      | 97.3 Days (Range: 76–120) (p < 0.05 versus Control)                             | 113.9 Days (Range: 89–120) (p < 0.05 versus Control & Monotherapy)                |
|           |                              |                             | Tumor Specific Lymphocyte Stimulation Index 2 Weeks After Treatment        | 88.49 SI (39.30 StdDev) (p < 0.05 versus Control)                               | 103.43 SI (55.33 StdDev) (p < 0.05 versus Control)                                 |
|           |                              |                             | Cytolytic Activity 2 Weeks After Treatment<sup>65</sup>                   | 487.79 RLU (148.69 StdDev) (Not Significant versus Control)                   | 972.72 RLU (362.77 StdDev) (p < 0.05 versus Control)                             |
|           |                              |                             | Rechallenge With Malignant Cells to Animals Surviving 160 Days             | All Animals Developed Pulmonary Metastases                                      | Pulmonary Metastases Developed in 2 out of 6 Animals                               |
| den Brok, M.H., et al. [10] | B16OVA Murine Melanoma     | Anti-CTLA-4 Antibodies      | OVA Rechallenge to Animals Surviving 40 Days                               | Used as Control with Sham IgG Antibodies                                        | Significant Increase in Percentage Survival Versus Control (p < 0.05)             |
|           |                              |                             | OVA kb Tetramer Positive CD8b + T Cells After 10 Days                     | 0.1% of CD8b + T Cells                                                         | 42% of CD8b + T Cells                                                           |
|           |                              |                             | Anti-CD25 Antibodies                                                     | OVA Rechallenge to Animals Surviving 40 Days                                    | Used as Control with Sham IgG Antibodies                                        |
|           |                              |                             |                                                                            | Significant Increase in Percentage Survival Versus Control (p < 0.05)          | Significant Increase in Percentage Survival Versus Control (p < 0.05)           |
|           |                              |                             |                                                                            | OVA kb Tetramer Positive CD8b + T Cells After 10 Days                          | 0.1% of CD8b + T Cells                                                         |
|           |                              |                             |                                                                            |                                                                                | 28% of CD8b + T Cells                                                          |
| Dromi, S.A., et al. [36] | MB49 Murine Urothelial Carcinoma | Intratumoral Injection of Immature Ex-Vivo Dendritic Cells | Median Tumor Volume Change                                                  | Significant Volume Loss Versus Control (p < 0.005 versus Control)              | No Significance Established Versus Control or Monotherapy (p = 0.07)             |
| Nakagawa, H., et al. [38] | MC38 Murine Colon Cancer   | Local Injection of OK-432 Stimulated Dendritic Cells                     | Mean Tumor Volume 10 Days After Treatment                                    | No Significant Established Versus Control                                       | Significant Volume Loss Versus Monotherapy (p < 0.001)                            |
| Liu, Q., et al. [39] | B16F10-luc Murine Melanoma | Heat-shocked Tumor Cell Lysate-pulsed Dendritic Cells                    | Percent Survival 100 Days After Treatment                                    | No Data                                                                          | Significantly Increased Versus Control & Monotherapy (p < 0.001)               |

<sup>65</sup> Denotes that the results are not statistically significant.

**Table 2: Studies that investigated the effects of combining radiofrequency ablation with immunomodulation and their results.**
Table 2: Studies that investigated the effects of combining radiofrequency ablation with immunomodulation and their results (Continued)

| Gameiro, S.R., et al. [40] | MC38 CEA+ Murine Colon Cancer | Poxviral Vaccine Expressing CEA and a Triad of Costimulatory Molecules (CEA/TRICOM) | IFN-γ Produced by CD+ T Cells Isolated From Draining Lymph Nodes After 2 Weeks | Tumor Cell Lysate Pulsed DC’s (p < 0.01) |
|--------------------------|--------------------------------|-----------------------------------------------------------------|-------------------------------------------------|------------------------------------------|
| Relapse Free Survival    | Primary & Distal Tumor Burden at Day 24 | Combined Volume Significantly Reduced Versus Control (p < 0.0001) | Combined Volume Significantly Reduced Versus Monotherapy (p < 0.0054) |
| Iida, N, et al., [41]    | BNL 1ME A7R.1 Murine Hepatoma | Active Variant of CC Chemokine Ligand 3 (EC301) | Tumor Volume After 14 Days | Significantly Reduced Compared to Control (p < 0.01) |
| CD4+ & CD8+ T Cell Infiltration After 3 Days | | | | Tumor Volume After 30 Days | Significantly Increased Versus Control (p < 0.01) |
| Shi, L, et al. [16]      | CT26 Murine Colon Cancer | Anti-PD-1 Antibodies | Tumor Volume After 30 Days | No Significance Established Versus Control |
| Total Survival After Inoculation | | | | Significantly Reduced Versus Monotherapy (p < 0.001) |

Cytolytic activity as measured by relative luminescence units (RLU) of adenylate kinase released by isolated peripheral blood T cells

NS, not significant
| Reference                  | Tumor Model                  | Immunotherapy                  | Endpoint                                                                 | Ablation Monotherapy                                    | Combination Therapy                                                                 |
|---------------------------|------------------------------|--------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------------------------|
| den Brok, M.H., et al. [12] | B16OVA Murine Melanoma       | CpG                             | Total Number of Dendritic Cells per Lymph Node 2 Days After Treatment    | No Significance Established Versus Control               | Significantly Increased Versus Monotherapy (\(p < 0.05\))                              |
|                           |                              |                                 | CD80 Expression on OVA Specific Dendritic Cells 2 Days After Treatment    | Significantly Increased Versus Control (\(p < 0.05\))     | Significantly Increased Compared to Monotherapy (\(p < 0.05\))                       |
|                           |                              |                                 | MHC Class I Presentation (B3Z Activation)                               | No Significance Established Versus Control               | Significantly Increased Versus Monotherapy (\(p < 0.05\))                              |
|                           |                              |                                 | MHC Class II Presentation (IL-2 Production)                             | Significantly Increased Versus Control (\(p < 0.05\))     | Significantly Increased Versus Monotherapy (\(p < 0.05\))                              |
|                           |                              |                                 | OVA Rechallenge to Animals Surviving 40 Days                             | Significantly Increased Survival Versus Control (\(p < 0.005\)) | Complete Protection Against Tumor Outgrowth (\(p < 0.005\))                           |
|                           |                              |                                 | Survival From Contralateral Metastasis                                  | No Significance Established Versus Control               | Significantly Prolonged Versus Monotherapy (\(p < 0.005\))                              |
|                           |                              |                                 | Local Recurrence Within 15 Days                                         | Significantly Higher Recurrence Versus Combination Therapy (\(p < 0.005\)) | Complete Protection Against Outgrowth of Local Recurrences                           |
| Machlenkin, A. [37]       | 3LL Murine Lewis Lung Carcinoma & B16OVA Murine Melanoma | Intratumoral Injection of Immature Dendritic Cells | Survival Following Amputation of Foot Bearing Primary Tumor | No Significance Established Versus Control               | Significantly Prolonged Versus Monotherapy (\(p = 0.005\))                             |
|                           |                              |                                 | Proliferation of Tumor Specific CD8+ T Cells                             | 35% of CD8+ T Cells Underwent Division                   | 66% of CD8+ T Cells Underwent Division                                                 |
|                           |                              |                                 | Rechallenge With Malignant Cells to Animals Surviving 60 Days            | No Significance Established Versus Control               | Significantly Prolonged Survival Versus Monotherapy (\(p = 0.029\))                  |
| Redondo, P., et al. [11]  | B16OVA Murine Melanoma       | Topical TLR-7 Agonist Imiquimod | Rechallenge With Malignant Cells to Animals Surviving 15 Days            | Significantly Delayed the Outgrowth of Secondary Tumors Compared to Control (\(p < 0.0001\)) | Significantly Protection Against Secondary Tumor Outgrowth Compared to Monotherapy (\(p < 0.0001\)) |
| Waitz, R., et al. [15]    | TRAMP C2 Murine Prostate Cancer | ipilimumab CTLA-4 Inhibition   | Tumor Free Survival                                                     | No Significance Established Versus Control               | Significantly Prolonged Versus Monotherapy (\(p < 0.0005\))                             |
|                           |                              |                                 | Challenge With Secondary Tumor After 1 Day                              | 0 out of 5 Mice Rejected the Secondary Tumor             | 4 out of 9 Mice Rejected the Secondary Tumor                                           |
|                           |                              |                                 | Number of Infiltrating CD4+ T Cells After 15 Days                       | No Significance Established Versus Control               | Significantly Increased Versus Control Only (\(p = 0.001–0.05\))                     |
| Study | Tumor Model | Treatment | Outcome | Immunological Effect | p Value |
|-------|-------------|-----------|---------|----------------------|---------|
| Levy, M.Y., et al. [44] | CT26 Murine Colon Cancer | Cyclophosphamide | Total Survival After Inoculation | Significance Not Established Versus Control (p = 0.46) | |
| | | | Rechallenge With Malignant Cells to Animals Surviving 150 Days | No Significance Established Versus Control | |
| den Brok, M.H., et al. [10] | B16OVA Murine Melanoma | Anti-CTLA-4 Antibodies | OVA Rechallenge to Animals Surviving 40 Days | Used as Control with Sham IgG Antibodies | |
| | | | OVA kb Tetramer Positive CD8b+ T Cells After 10 Days | 0.1% of CD8b+ T Cells | 5.8% of CD8b+ T Cells |
| | | Anti-CD25 Antibodies | OVA Rechallenge to Animals Surviving 40 Days | Used as Control with Sham IgG Antibodies | |
| | | | OVA kb Tetramer Positive CD8b+ T Cells After 10 Days | 0.1% of CD8b+ T Cells | 5.0% of CD8b+ T Cells |
| Reference     | Tumor Model | Immunotherapy | Endpoint                                      | Ablation Monotherapy                                                                 | Combination Therapy                                                                 |
|---------------|-------------|---------------|-----------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Li, L., et al. [42] | 4 T1 Murine Breast Cancer | OK-432        | Total Survival After Treatment                | No Significance Established Versus Control                                              | Significantly Prolonged Compared to Monotherapy (p < 0.001)                        |
|               |             |               | Rechallenge to Surviving Mice 25 Days After Treatment | No Data                                                                              | Significantly Decreased Tumor Volume Versus Control After 25 Days (p < 0.05)        |
|               |             |               | Infiltration of CD4+ T Cells Into Tumors       | Significantly Increased Versus Control (p < 0.001)                                    | Significantly Increased Versus Control NOT Monotherapy (p < 0.001)                  |
|               |             |               | Infiltration of CD8+ T Cells Into Tumors       | Significantly Increased Versus Control (p < 0.001)                                    | Significantly Increased Versus Monotherapy (p < 0.01)                               |
|               |             |               | Percentage of Splenic CD4+ T Cells             | Significantly Increased Versus Control (p < 0.001)                                    | Significantly Increased Versus Monotherapy (p < 0.05)                               |
|               |             |               | Percentage of Splenic CD8+ T Cells             | Significantly Increased Versus Control (p < 0.001)                                    | Significantly Increased Versus Monotherapy (p < 0.01)                               |
|               |             |               | Number of 4 T1 Specific IFN-γ Secreting Cells  | Significantly Increased Versus Control (p < 0.001)                                    | Significantly Increased Versus Monotherapy (p = 0.031)                               |
|               |             |               | Ratio of Th1 to Th2 Cytokines Produced by CD4+ T Cells | No Significance Established Versus Control                                             | Significantly Increased Versus Monotherapy (p < 0.05)                               |
| Chen, Z., et al. [45] | Hepa 1–6 Murine Hepatoma | Intratumoral Microspheres Encapsulating GM-CSF | Tumor Free Survival Following Rechallenge to Animals Surviving 8 Weeks               | Used as Control with Sham BSA Microspheres                                           | Significant Increase in Percent Tumor Free Survival Versus Monotherapy After 6–7 Weeks (p < 0.01) |
|               |             |               | Tumor Volume Following Rechallenge to Animals Surviving 8 Weeks | Used as Control with Sham BSA Microspheres                                           | Significant Decrease Versus Monotherapy After 8 Weeks (p = 0.0183)                 |
|               |             | GM-CSF Microspheres + Anti-CTLA-4 Antibodies | Tumor Free Survival Following Rechallenge to Animals Surviving 8 Weeks | MWA/GM-CSF/Sham IgG Antibodies Used as Control                                       | Significant Increase in Percent Tumor Free Survival Versus Control After 6–7 Weeks (p = 0.0189) |
|               |             |               | Tumor Volume Following Rechallenge to Animals Surviving 8 Weeks | MWA/GM-CSF/Sham IgG Antibodies Used as Control                                     | Significant Decrease in Tumor Volume Versus Control After 8 Weeks (p < 0.02)       |
|               |             |               | Total Survival After Inoculation               | MWA/GM-CSF/Sham IgG Antibodies Used as Control                                       | Significantly Prolonged Compared to Control (p < 0.002)                           |
onto in vivo dendritic cells was more efficient with cryoablation than RFA, as measured by using CD11+ beads to sort out dendritic cells [14]. Additional research has shown that adding the CTLA-4 inhibitor Ipilimumab to cryoablation therapy confers an improved response in a mouse model of prostate cancer. When compared to either therapy alone, combination therapy significantly increased the infiltration of CD4+ and CD8+ T cells into tumors and elevated the ratio of effector CD4+ cells to regulatory FoxP3+ T cells as compared to monotherapy ($p < 0.01$–$0.05$). Additionally, the authors showed that combination therapy significantly prolonged tumor free survival ($p < 0.0005$). Finally, they demonstrated that following a challenge with a new secondary tumor 1 day after treatment, none of the mice receiving cryoablation alone rejected the tumor whereas almost half of the mice receiving combination therapy did [35].

Den Brok et al. also demonstrated the effectiveness of combining ablation with anti-CD25 antibodies. Both cryoablation and RFA in combination with anti-CD25 antibodies showed a significant increase in survival following rechallenge compared ($p < 0.05$). The percentage of OVA kb tetramer positive CD8b + T cells 10 days after treatment was also quantified. Following both RFA/anti-CD25 and Cryoablation/anti-CD25 therapy, the percentage increased, but it did not increase following monotherapy [14]. Cyclophosphamide has also been used to deplete regulatory T cells prior to cryoablation of a solid malignancy. When Cyclophosphamide was combined with cryoablation in a murine colorectal model, the proliferation of tumor specific T cells was greatly increased as was the ratio of effector CD4+ T cells to regulatory FoxP3+ T cells. Survival in animals that received combination therapy was significantly prolonged and the combination also significantly increased protection against rechallenge with malignant cells after 150 days of survival ($p < 0.0001$ & $p = 0.0051$). This increased antitumor immunity was successfully transferred to naive animals by injecting them with lymphocytes from tumor draining lymph nodes of the treated animals. The transfer of immunity was dependent on the presence of CD8+ T cells from treated animals. Removal of CD4+ T cells from the infusate had no effect on the conferred immunity. This indicates that CD8+ T cells are the main effector of antitumor immunity [53].

Another study found that addition of anti-PD-1 antibodies to RFA in a murine colon cancer model overcomes a major checkpoint to a systemic immune response. They found that tumors significantly upregulated the regulatory co-stimulators PD-1 in response to RFA. By adding PD-1 inhibition to RFA, they achieved significant a decrease in tumor volume and a significant increase in survival ($p < 0.001$) [54].

Chen et al. conducted a unique study that compared the effects of an innate immunotherapy plus microwave ablation to a combination of innate and adaptive immunotherapies plus microwave ablation. First off, they combined an intratumoral injection of microspheres encapsulating granulocyte-macrophage colony stimulating factor (GM-CSF) with microwave ablation in a murine model of hepatoma. They chose GM-CSF microspheres because GM-CSF is known to be highly efficacious at recruiting and activating dendritic cells. The albumin based spheres released GM-CSF over 3 days, and 3 separate injections were given. Bovine Serum Albumin Microspheres (sham-BSA) were used a control. Following a rechallenge with malignant cells 8 weeks after treatment, microwave ablation combined with GM-CSF was shown to significantly increase the percent of animals surviving tumor-free and to significantly decrease the tumor volume ($p < 0.01$ & $p = 0.0183$). The response to treatment was even more profound with the addition of anti-CTLA-4 antibodies for a combined MWA/GM-CSF/anti-CTLA-4 therapy. This 3 therapy combination significantly increased total survival after initial inoculation compared to untreated animals ($p < 0.002$). Additionally, after rechallenge the combination significantly increased the percentage of mice surviving tumor-free and significantly decreased the volume of tumors in mice 6–7 weeks after rechallenge ($p = 0.0189$ & $p < 0.02$). Furthermore the triple therapy protected against rechallenge in almost all of the mice treated, and cured distal tumors in half of the mice with small tumor burden [55] (Tables 2, 3 and 4).

**Conclusion**

The benefits of combining immunotherapy with ablation continue to be unraveled. In particular, much work still needs to be done to elucidate the effects induced through the combination of ablation with immunotherapies that target the adaptive immune system. Regardless, the synergistic enhancement of the antitumor immune response exhibited by the combination therapies in these early studies shows great promise for the future of oncologic treatment.

**Abbreviations**

ATP: Adenosine triphosphate; BSA: Bovine serum albumin; CD: Cluster of differentiation; CEA: Carcinomaembryonic antigen; CpG ODN: CpG oligodeoxynucleotides; CTLA-4: Cytotoxic T lymphocyte-associated antigen 4; DAMPs: Damage associated molecular patterns; DCs: Dendritic cells; FoxP3: Forkhead box P3; FUS: Focused ultrasound; GM-CSF: Granulocyte-macrophage colony stimulating factor; HIFU: High Intensity Focused ultrasound; HMBG1: High mobility group protein B1; HSPs: Heat shock proteins; HT-DC: Heat-Shocked Tumor Cell lysate-pulsed dendritic cells; IFN-γ: Interferon γ; LOFU: Low energy focused ultrasound; MHC: Major histocompatibility complex; MWA: Microwave ablation; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; PD: Programmed death receptor; RFA: Radiofrequency ablation; RLU: Relative luminescence units; SABR: Stereotactic ablative radiotherapy; SBRT: Stereotactic body radiation therapy; SL: Stimulation index; TGF-β: Transforming growth factor beta 1/2; TLR: Toll-like receptor; TNF-α: Tumor necrosis factor alpha; TGF-β: Transforming growth factor beta 1/2; TLR: Toll-like receptor; TNF-α: Tumor necrosis factor alpha.
necrosis factor alpha; TRICOM: Triad of costimulatory molecules; VEGF: Vascular endothelial growth factor; Y90: Yttrium 90

Acknowledgements
Not applicable.

Ethical approval and consent to participate
Not applicable.

Funding
The authors declare that no funding was used in the writing of this review.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Authors’ contributions
RS contributed to the writing, literature search, interpret data, figure and table design, and editing. JML contributed to the writing, literature search, interpret data, figure and table design and editing. SNG contributed to the writing, figure and table design, critical review and editing. RSH contributed to the critical review and editing. HSK contributed to the concept, planning, writing, figure and table design, editing, funding, resources and supervision. All authors have read and approved the final manuscript.

Consent for publication
Not applicable.

Competing interests
All authors have no financial or other relationship with any commercial organization that may have a direct or indirect interest in this manuscript.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 330 Cedar Street, New Haven, CT 06510, USA. 2University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06032, USA. 3Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany. 4Division of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, 330 Cedar Street, New Haven, CT 06510, USA. 5Yale Cancer Center, Yale School of Medicine, New Haven, 330 Cedar Street, New Haven, CT 06510, USA. 6Yale School of Medicine, Yale Cancer Center, 333 Cedar Street, P.O. Box 208042, New Haven, CT 06520, USA.

Received: 13 July 2017 Accepted: 5 September 2017
Published online: 17 October 2017

References
1. Sag AA, Selcukbircik F, Mandel NM. Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol. 2016;22(11):3127–49.
2. Mehta A, Oku R, Sheth RA. Thermal Ablative Therapies and Immune Checkpoint Modulation: Can LocoRegional Approaches Effect a Systemic Response? Gastroenterol Res Pract. 2016;2016:9251375.
3. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208.
4. van der Bijaart RJF, et al. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother. 2017;66(2):247–58.
5. Bandypadhyay S, et al. Low-Intensity Focused Ultrasound Induces Reversal of Tumor-Induced T Cell Tolerance and Prevents Immune Escape. J Immunol. 2016;196(4):1964–76.
6. Ng J, Dai T. Radiation therapy and the abscopal effect: a concept comes of age. Annals of Translational Medicine. 2016;4(8):118.
7. Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cytotherapy. 2009;11(1):1–11.
8. McArthur HL, et al. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cytosine Arabinoside in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clin Cancer Res. 2016;22(23):5729–37.
9. Page DB, et al. Deep Sequecing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunol Res. 2016;4(10):835–44.
10. Duffy AG, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545–51.
11. Xue J, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014;40(2):274–88.
12. Basu S, et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κappa B pathway. Int Immunol. 2000;12(1):1539–46.
13. Bottero V, Wiltsho SV, Verma IM. NK-kappa B and the regulation of hematopoiesis. Cell Death Differ. 2006;13(5):785–97.
14. den Brok MH, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer. 2006;95(7):896–905.
15. Redondo P, et al. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol. 2007;127(7):1673–80.
16. den Brok MH, et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res. 2006;66(14):7285–92.
17. Baust JC, Gage AA. The molecular basis of cryosurgery. Biomedicine. 2005;50(9):1187–91.
18. Sabel MS, et al. Rate of freeze alters the immunologic response after cryoablation of breast cancer. Ann Surg Oncol. 2010;17(4):1187–93.
19. Fietta AM, et al. Systemic inflammatory response and down modulation of peripheral CD25+Foxp3+ Tregulatory cells in patients undergoing radiofrequency ablation for lung cancer. Hum Immunol. 2009;70(7):477–86.
20. Widenmeyer M, et al. Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer. 2011;128(11):2653–62.
21. Ahmed M, et al. Hepatic Radiofrequency Ablation-induced Stimulation of Distant Tumor Growth Is Suppressed by c-Met Inhibition. Radiology. 2016;279(1):103–17.
22. Nijkamp MW, et al. Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon. Ann Surg. 2009;249(5):814–23.
23. Ahmad F, et al. Changes in interleukin-1beta and 6 after hepatic microwave tissue ablation compared with radiofrequency, cryotherapy and surgical resections. Am J Surg. 2010;200(4):500–6.
24. Ahmad F, et al. Radiofrequency microwave ablation compared with radiofrequency, cryotherapy and surgical resection at different volumes of the liver treated. Liver Int. 2010;30(9):1305–14.
25. Wu F, Zhou L, Chen WR. Host antitumor immune responses to HFU ablation. Int J Hyperth. 2007;23(2):165–71.
26. Ghodadra A, et al. Abscopal Effects and Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol. 2016;39(7):1076–80.
27. Verbrugge L, et al. Radiotherapy increases the permeability of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012;72(11):3163–74.
28. Dewan MZ, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(7):5379–88.
29. Teitz-Tennenbaum S, et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res. 2006;66(23):8466–75.
30. Wang C, et al. Immunological Responses Triggered by Photothermal Therapy with Carbon Nanotubes in Combination with Anti-CTLA-4 Therapy to Inhibit Cancer Metastasis. Adv Mater. 2014;26(48):8154–62.
31. Chen Q, et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun. 2016;7:13193. https://doi.org/10.1038/ncomms13193.
32. Dempsey PW, Vaidya SA, Cheng G. The art of war: Innate and adaptive immune responses. Cell Mol Life Sci. 2003;60(12):2604–21.
34. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39(1):98–106.
35. Waitz R, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012;72(2):490–9.
36. Saha A, Chatterjee SK. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumor immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand J Immunol. 2010;71(2):70–82.
37. Bulliard Y, et al. Activating FC receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210(9):1685–93.
38. Peggi K, et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206–13.
39. Couper KN, et al. Anti-CD25 antibody mediated depletion of effector T cell populations enhances susceptibility of mice to acute, but not chronic, Toxoplasma gondii infection. Journal of Immunology (Baltimore, Md : 1950). 2009;182(7):3985–94.
40. Behm B, et al. Additive antitumour response to the rabbit VK2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation. Gut. 2016;65(1):134–43.
41. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5(6):471–84.
42. Asselin-Paturel C, et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med. 2005;201(7):1157–67.
43. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709–60.
44. Nierkens S, et al. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One. 2009;4(12):e8368.
45. Dromi SA, et al. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology. 2009;251(1):58–66.
46. Machenkin A, et al. Combined dendritic cell cryotherapy of tumor induces systemic antitumour immunity. Clin Cancer Res. 2005;11(13):4955–61.
47. Nakagawa H, et al. In vivo immunological antitumor effect of OK-432-stimulated dendritic cell transfer after radiofrequency ablation. Cancer Immunol Immunother. 2002;2:709–60.
48. Liu Q, et al. Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine. Mol Ther. 2009;17(12):2049–57.
49. Gameiro SR, et al. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One. 2013;8(7):e70417.
50. Iida N, et al. Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC Chemokine ligand 3/macrophage inflammatory protein-1alpha. Cancer Res. 2010;70(16):6556–65.
51. Li L, et al. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer. J Transl Med. 2017;15:233.
52. den Brok MH, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004;64(11):4024–9.
53. Levy MY, et al. Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation. J Pharmacol Exp Ther. 2009;330(2):596–601.
54. Shi L, et al. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res. 2016;22(5):1173–84.
55. Chen Z, et al. Intratumoral GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model. Int J Hyperth. 2009;25(3):374–82.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit